TABLE 2.

24 h urine protein decline rates and the treatment effectiveness rate two groups.

Parameters	Control group (n = 31)	CRT group (n = 30)	P-value
Baseline 24 h urine protein M (Q1, Q3), g	3.98 (1.95, 4.77)	4.42 (2.13, 7.75)	0.428
1M 24 h urine protein M (Q1, Q3), g	3.44 (2.90, 6.63)	3.67 (1.68, 5.46)	0.908
1M 24 h urine protein decline rate, M, %	16%	22%	0.614
2M 24 h urine protein, M (Q1, Q3), g	3.34 (1.73, 5.18)	3.29 (1.89, 4.63)	0.708
2M 24 h urine protein decline rate, M, %	26%	34%	0.428
3M 24 h urine protein, M (Q1, Q3), g	3.22 (2.40, 5.91)	2.68 (2.03, 3.45)	0.535
3M 24 h urine protein decline rate, M, %	41%	51%	0.507
Treatment effectiveness rates, n (%)	22 (70.97%)	28 (93.33%)	0.023
Adverse events rates, n (%)	1 (3.23%)	3 (10%)	0.581
Liver injury, n (%)	1 (3.23%)	1 (3.33%)
Gastrointestinal adverse reactions, n (%)	0 (0%)	2 (6.67%)